A randomized double-blinded placebo-controlled trial of benr…
A randomized double-blinded placebo-controlled trial of benralizumab for prevention of asthma exacerbations in patients with moderate to severe persistent asthma was conducted. At the end of the trial, 356 out of 1358 subjects in the benralizumab arm and 476 out of 1332 subjects in the placebo arm had one or more exacerbations during the trial period. Calculate the relative risk for asthma exacerbations when using benralizumab from this trial.